Market Overview:
The global recombinant human insulin market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in the field of recombinant human insulin. The recombinant human insulin market is segmented on the basis of type, application, and region. On the basis of type, it is divided into recombinant DNA technology using fermentation in bacteria way and recombinant DNA technology using fermentation in yeast way. Recombinant DNA technology using fermentation in bacteria way dominates this market owing to its low cost as compared to other technologies used for manufacturing recombinant human insulin. On the basis of application, it is classified into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T2DM accounts for a larger share of this market owing to rising incidence rates across all regions globally. Geographically, it is analyzed across North America, Latin America, Europe Asia Pacific & Middle East & Africa (MEA).
Product Definition:
Recombinant human insulin is a biosynthetic form of the hormone, insulin, which is used to treat diabetes mellitus. It is made by genetically altering bacteria to produce the protein. The recombinant form is more pure than animal-derived insulin and has a longer shelf life. It also causes fewer allergic reactions in people with diabetes.
by Recombinant DNA Technology Using Fermentation in Bacteria Way:
Ans) Recombinant DNA technology is used to construct a gene for the production of human insulin. The recombinant DNA technique is used as a method, which can generate an almost identical copy of any particular gene. This process involves the use of bacteria as carriers to carry out the transformation or transfection procedure.
The main steps involved in this technology are; isolation & purification, ligation & amplification, and lastly - conversion into mature form ( mRNA).
by Recombinant DNA Technology Using Fermentation in Yeast Way:
It is a process of making DNA from the genes which are extracted from one or more organisms and then put together in order to form new genetic material. This recombinant DNA technology uses fermentation in yeast way for the extraction of nucleic acids.
Application Insights:
On the basis of application, the global market has been segmented into type 1 diabetes mellitus and type 2 diabetes mellitus. In 2017, the type 2 diabetes segment dominated with a share of 59.1% in terms of revenue as well as volume. This is due to an increase in incidence rates coupled with a growing awareness about preventive measures for this disease across all age groups globally. Type 1 diabetes is more prevalent among children and adolescents along with obese/ overweight individuals who have not been exposed to any form of insulin or haven¢â‚¬â„¢t used it before.
The introduction of new drugs that are easier for patients to take along with a reduced dosage schedule will open up new avenues for recombinant human insulin globally over the forecast period especially in North America.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large patient pool and high adoption of innovative technologies. Moreover, increasing prevalence of obesity and diabetes is expected to drive regional growth over the forecast period. Asia Pacific is expected to grow at a lucrative rate during the forecast period due to rising disposable income, improving healthcare infrastructure, and an increase in awareness about insulin therapies among patients. Furthermore, government initiatives for developing new products are anticipated to boost demand for insulin recombinants over the next eight years. For instance, Novo Nordisk along with its research partners developed zinc-infused protamine zinc insulin (ZIH) that helps reduce blood sugar levels faster than regular human insulin after meals High level of Zinc reduces risk factors associated with type 2 diabetes such as cardiovascular diseases by 40% thus reducing overall development cost by 60%.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for recombinant human insulin in the coming years.
- Rising awareness about diabetes and its treatment options: There is a growing awareness among people about diabetes and its treatment options, including recombinant human insulin therapy. This is likely to boost the demand for this product in the near future.
- Technological advancements in insulin delivery devices: There have been significant advancements in insulin delivery devices over the past few years, which has made it easier and more convenient for patients to administer recombinant human insulin therapy. This is likely to fuel market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Insulin Market Research Report
By Type
by Recombinant DNA Technology Using Fermentation in Bacteria Way, by Recombinant DNA Technology Using Fermentation in Yeast Way
By Application
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
By Companies
Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories, Dongbro Pharmaceuticri
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Insulin Market Report Segments:
The global Recombinant Human Insulin market is segmented on the basis of:
Types
by Recombinant DNA Technology Using Fermentation in Bacteria Way, by Recombinant DNA Technology Using Fermentation in Yeast Way
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Akron Biotech
- Wockhardt
- Dance Biopharm
- Novo Nordisk
- Gan & Lee
- United Laboratories
- Dongbro Pharmaceuticri
Highlights of The Recombinant Human Insulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- by Recombinant DNA Technology Using Fermentation in Bacteria Way
- by Recombinant DNA Technology Using Fermentation in Yeast Way
- By Application:
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Insulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human insulin is a type of insulin that has been made in a laboratory. It is different from regular human insulin because it has been modified so that it can be absorbed more easily by the body. This makes it easier for people with diabetes to control their blood sugar levels.
Some of the major players in the recombinant human insulin market are Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories, Dongbro Pharmaceuticri.
The recombinant human insulin market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Recombinant Human Insulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Recombinant Human Insulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Recombinant Human Insulin Market - Supply Chain
4.5. Global Recombinant Human Insulin Market Forecast
4.5.1. Recombinant Human Insulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Recombinant Human Insulin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Recombinant Human Insulin Market Absolute $ Opportunity
5. Global Recombinant Human Insulin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Recombinant Human Insulin Market Size and Volume Forecast by Type
5.3.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
5.3.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Recombinant Human Insulin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Recombinant Human Insulin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Recombinant Human Insulin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Recombinant Human Insulin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Recombinant Human Insulin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Recombinant Human Insulin Demand Share Forecast, 2019-2026
9. North America Recombinant Human Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Recombinant Human Insulin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Recombinant Human Insulin Market Size and Volume Forecast by Type
9.7.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
9.7.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Recombinant Human Insulin Demand Share Forecast, 2019-2026
10. Latin America Recombinant Human Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Recombinant Human Insulin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Recombinant Human Insulin Market Size and Volume Forecast by Type
10.7.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
10.7.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Recombinant Human Insulin Demand Share Forecast, 2019-2026
11. Europe Recombinant Human Insulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Recombinant Human Insulin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Recombinant Human Insulin Market Size and Volume Forecast by Type
11.7.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
11.7.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Recombinant Human Insulin Demand Share, 2019-2026
12. Asia Pacific Recombinant Human Insulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Recombinant Human Insulin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Recombinant Human Insulin Market Size and Volume Forecast by Type
12.7.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
12.7.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Recombinant Human Insulin Demand Share, 2019-2026
13. Middle East & Africa Recombinant Human Insulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Recombinant Human Insulin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Recombinant Human Insulin Market Size and Volume Forecast by Application1 Diabetes Mellitus2 Diabetes Mellitus
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Recombinant Human Insulin Market Size and Volume Forecast by Type
13.7.1. by Recombinant DNA Technology Using Fermentation in Bacteria Way
13.7.2. by Recombinant DNA Technology Using Fermentation in Yeast Way
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Recombinant Human Insulin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Recombinant Human Insulin Market: Market Share Analysis
14.2. Recombinant Human Insulin Distributors and Customers
14.3. Recombinant Human Insulin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Akron Biotech
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Wockhardt
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Dance Biopharm
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novo Nordisk
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Gan & Lee
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. United Laboratories
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dongbro Pharmaceuticri
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
